Clotbusting Powers of tPA: Beside the Point in Stroke?
By Anette Breindl
Science Editor
Science Editor
Wednesday, August 8, 2012
Tissue-plasminogen activator (tPA, sold as Activase by Roche AG) is the only stroke treatment that has made it to the market at all, amidst a bevy of failed attempts to develop additional stroke drugs. But its limitations are twofold.
To continue reading subscribe now to Science News
Learn More about Science News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.